Tyrosyl-tRNA synthetase inhibitors: a patent review

References

• Barker JJ. Antibacterial drug discovery and structure-based design. Drug Discov Today. 2006;11:391–404.
   PubMed Web of Science ®Google Scholar
• Nasr T, Bondock S, Eid S. Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety. Eur J Med Chem. 2014;84:491–504.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of america. Clin Infect Dis. 2009;48:1–12.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance global report on surveillance: 2014 summary. 2014.
   Google Scholar
• Prescott F, Patricia MD. Antimicrobial therapy in veterinary medicine. John Wiley & Sons Books; 2013.
   Google Scholar
• Fjell CD, Hiss JA, Hancock REW, et al. Designing antimicrobial peptides: form follows function. Nature Reviews Drug Discovery. 2012;11:37–51.
   Web of Science ®Google Scholar
• Vondenhoff GHM, Aerschot AV. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem. 2011;46:5227–5236.
   PubMed Web of Science ®Google Scholar
• Schimmel P, Tao J, Hill J. Aminoacyl tRNA synthetases as targets for new anti-infectives. Faseb J. 1998;12:1599–1609.
   PubMed Web of Science ®Google Scholar
• Arnez JG, Moras D. Structural and functional considerations of the aminoacylation reaction. Trends Biochem Sci. 1997;22:211–216.
   PubMed Web of Science ®Google Scholar
• Guo M, Schimmel P. Essential nontranslational functions of tRNA synthetases. Nat Chem Biol. 2013;9:145–153.
   PubMed Web of Science ®Google Scholar
• Burbaum JJ, Schimmel P. Structural relationships and the classification of aminoacyl-tRNA synthetases. J Biol Chem. 1991;266:16965–16968.
   PubMed Web of Science ®Google Scholar
• Gadakh B, Van AA. Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: a patent review from 2006 till present. Expert Opin Ther Pat. 2012;22:1453–1465.
   PubMed Web of Science ®Google Scholar
• Bullard JM, Hu YM, Palmer SO Antibiotic compounds that inhibit bacterial protein synthesis. US2016220510A1, 2016.
   Google Scholar
• Cochereau C, Sanchez D, Bourhaoui A, et al. Capsaicin, a structural analog of tyrosine, inhibits the aminoacylation of tRNATyr. Toxicol Appl Pharmacol. 1996;141:133–137.
   PubMed Web of Science ®Google Scholar
• Watkins JD, Vasserot AP, Belani R, et al. Antibodies that bind Tyrosyl-tRNA synthetases. US8828395B2, 2014.
   Google Scholar
• Stefanska AL, Coates NJ, Mensah LM, et al. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases. US2015/0353914A1, 2015.
   Google Scholar
• Lawlor EJ, Hodgson JE, Malvern P Tyrosyl tRNA synthetase polynucleotides. US6071892, 2000.
   Google Scholar
• Houge-Frydrych CS, Readshaw SA, Bell DJ. SB-219383, a novel tyrosyl tRNA synthetase inhibitor from a micromono-spora spII. Structure determination. J Antibiot. 2000;53:351–356.
   PubMed Web of Science ®Google Scholar
• Berge JM, Copley RCB, Eggleston DS, et al. Inhibitors of bacterial tyrosyl trna synthetase: synthesis of four stereoisomeric analogues of the natural product SB-219383. Bioorg Med Chem Lett. 2000;10:1811–1814.
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Berge JM, Houge-Frydrych CSV, et al. Inhibitors of bacterial tyrosyl trna synthetase: synthesis of carbocyclic analogues of the natural product SB-219383. Bioorg Med Chem Lett. 2001;11:2499–2502.
   PubMed Web of Science ®Google Scholar
• Brown P, Eggleston DS, Haltiwanger RC, et al. Synthetic analogues of SB-219383. novel C-glycosyl peptides as inhibitors of tyrosyl tRNA synthetase. Bioorganic Medicinal Chemistry Letters. 2001;11:711–714.
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Berge JM, Brown P, et al. Potent synthetic inhibitors of tyrosyl tRNA synthetase derived from C-pyranosyl analogues of SB-219383. Bioorganic Medicinal Chemistry Letters. 2001;11:715–718.
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Berge JM, Houge-Frydrych CSV, et al. Interaction of tyrosyl aryl dipeptides with S. aureus tyrosyl tRNA synthetase: inhibition and crystal structure of a complex. Bioorganic Medicinal Chemistry Letters. 1999;9:2859–2862.
   PubMed Web of Science ®Google Scholar
• Jiang S, Tala SR, Lu H, et al. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl) phenyl) thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. J Med Chem. 2010;54:572–579.
   PubMed Web of Science ®Google Scholar
• Jois VH, Kalluraya B, Girisha KS. Synthesis and antioxidant activity study of pyrazoline carrying an arylfuran/arylthiophene moiety. J Serbian Chem Soc. 2014;79:1469–S172.
   Web of Science ®Google Scholar
• Arlot Y, Martin B, Delcros JG, et al. Anti-tubulin acting arylpyrrol, arylfuran and arylthiophene derivatives, method for the preparation thereof and for the use thereof as an antimitotic. US8106089. 2012.
   Google Scholar
• Varshney MM, Husain A, Parcha V. Synthesis, characterization, in vitro antimicrobial, and anthelmintic evaluations of 2-(4-chloro-3-methylphenoxy)-N-[{5-(substituted aryl)-furan-2-yl}-methylidene]-acetohydrazides. Med Chem Res. 2014;23:4034–4041.
   Web of Science ®Google Scholar
• Xiao ZP, He XB, Peng ZY, et al. Synthesis, structure, molecular docking, and structure–activity relationship analysis of enamines: 3-aryl-4-alkylaminofuran-2 (5H)-ones as potential antibacterials. Bioorganic Medicinal Chemistry. 2011;19:1571–1579.
   PubMed Web of Science ®Google Scholar
• Xiao ZP, Ma TW, Liao ML, et al. Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: synthesis, molecular docking and structureeactivity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones. Eur J Med Chem. 2011;46:4904–4914.
   PubMed Web of Science ®Google Scholar
• Xiao ZP, Ouyang H, Wang XD, et al. 4-Alkoxy-3-arylfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation. Bioorg Med Chem. 2011;19:3884–3891.
   PubMed Web of Science ®Google Scholar
• Wang XD, Deng RC, Dong JJ, et al. 3-Aryl-4-acyloxyethoxyfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation. Bioorg Med Chem. 2013;21:4914–4922.
   PubMed Web of Science ®Google Scholar
• Brown P, Richardson CM, Mensah LM, et al. Molecular recognition of tyrosinyl adenylate analogues by prokaryotic tyrosyl tRNA synthetases. Bioorganic Medicinal Chemistry. 1999;7:2473–2485.
   PubMed Web of Science ®Google Scholar
• Wei W, Shi WK, Wang PF, et al. Adenosine analogs as inhibitors of tyrosyl-tRNA synthetase: design,synthesis and antibacterial evaluation. Bioorganic Medicinal Chemistry. 2015;23:6602–6611.
   PubMed Web of Science ®Google Scholar
• Jarrad AM, Debnath A, Miyamoto Y, et al. Nitroimidazole carboxamides as antiparasitic agents targeting giardia lamblia, entamoeba histolytica and trichomonas vaginalis. Eur J Med Chem. 2016;120:353–362.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Kalisiak J, Korthals K, et al. Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. Proc Natl Acad Sci. 2013;110:17564–17569.
   PubMed Web of Science ®Google Scholar
• Upton AM, Cho S, Yang TJ, et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:136–144.
   PubMed Web of Science ®Google Scholar
• Upton AM, Cho S, Yang TJ, et al. In vitro and in vivo activity against M. tuberculosis of the nitroimidazole TBA-354. Antimicrob Agents Chemother. 2014;59:136-144.
   Google Scholar
• Stevens V, Nelson R, Khader K, et al. Recurrence and mortality following treatment for clostridum difficile infection with metronidazole or vancomycin. Antimicrob Resist Infect Control. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Lewis BB, Buffie CG, Carter RA, et al. Loss of microbiota-mediated colonization resistance to clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis. 2015;212:1656–1665.
   Google Scholar
• Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802–807.
   PubMed Web of Science ®Google Scholar
• Kong D, Lu J, Ye S, et al. Synthesis and biological evaluation of a novel asymmetrical 99mTc-nitrido complex of metronidazole derivative. J Labelled Compounds Radiopharm. 2007;50:1137–1142.
   Web of Science ®Google Scholar
• Yong J, Lu C, Wu X. synthesis of metronidazole derivatives containing pyridine ring and anticancer activity. Lett Org Chem. 2016;13(4):283–288.
   Web of Science ®Google Scholar
• Rezaei Z, Khabnadideh S, Sadeghpour H, et al. synthesis and biological evaluation of metronidazole derivatives as anti-giardia agents. Trends Pharm Sci. 2015;1:105–110.
   Google Scholar
• Wang SF, Yin Y, Qiao F, et al. Synthesis, molecular docking and biological evaluation of metronidazole derivatives containing piperazine skeleton as potential antibacterial agents. Bioorg Med Chem. 2014;22:2409–2415.
   PubMed Web of Science ®Google Scholar
• Guo ZH, Yin Y, Wang C, et al. Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents. Bioorganic Medicinal Chemistry. 2015;23:6148–6156.
   PubMed Web of Science ®Google Scholar
• Chen LW, Wang PF, Tang DJ, et al. metronidazole containing pyrazole derivatives potently inhibit tyrosyl-trna synthetase: design, synthesis and biological evaluation. Chemical Biology Drug Design. 2016; 88:592–598.
   Web of Science ®Google Scholar
• Defoirdt T, Benneche T, Brackman G, et al. A quorum sensing-disrupting brominated thiophenone with a promising therapeutic potential to treat luminescent vibriosis. Plos One. 2012;7:e41788.
   Google Scholar
• Yanagimoto K, Lee KG, Ochi H, et al. Antioxidative activity of heterocyclic compounds found in coffee volatiles produced by maillard reaction. J Agric Food Chem. 2002;50:5480–5484.
   PubMed Web of Science ®Google Scholar
• Hurdle JG, O’Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother. 2005;49:4821–4833.
   PubMed Web of Science ®Google Scholar
• Benneche T, Herstad G, Rosenberg M, et al. Facile synthesis of 5-(alkylidene) thiophen-2 (5H)-ones. A new class of antimicrobial agents. RSC Adv. 2011;1:323–332.
   Web of Science ®Google Scholar
• Sun J, Liu JJ, Zhou W, et al. 4-Hydroxy-3-(naphthalen-1-ylmethyl)thiophen-2(5H)-one as inhibitors of tyrosyl-tRNA synthase: synthesis, molecular docking and antibacterial evaluation. J Mol Struct. 2014;1056-1057:104–109.
   Web of Science ®Google Scholar
• Colombo F, Tintori C, Furlan A, et al. ‘Click’ synthesis of a triazole-based inhibitor of met functions in cancer cells. Bioorganic Medicinal Chemistry Letters. 2012;22:4693–4696.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Johnson HWB, Jeong JW, et al. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem. 2012;55:1368–1381.
   PubMed Web of Science ®Google Scholar
• Furlan A, Colombo F, Kover A, et al. Identification of new amino acid amides containing the imidazo [2,1-b] benzothiazol-2-ylphenyl moiety as inhibitors of tumor genesis by oncogenic Met signaling. Eur J Med Chem. 2012;47:239–254.
   PubMed Web of Science ®Google Scholar
• Lemm JA, Leet JE, O’Boyle DR, et al. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother. 2011;5:3795–3802.
   Web of Science ®Google Scholar
• Xiao ZP, Wei W, Wang PF, et al. Synthesis and evaluation of new tyrosyl-tRNA synthetase inhibitors as antibacterial agents based on a N2-(arylacetyl)glycinanilide scaffold. Eur J Med Chem. 2015;102:631–638.
   PubMed Web of Science ®Google Scholar
• Brennan PJ. Structure, function, and biogenesis of the cell wall of mycobacterium tuberculosis. Tuberculosis. 2003;83:91–97.
   PubMed Web of Science ®Google Scholar
• Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–544.
   PubMed Web of Science ®Google Scholar
• Gomez JE, McKinney JDM. tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004;84:29–44.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Multidrug and extensively drug-resistant TB. 2010.
   Google Scholar
• Sathya R, Thamotharan S. In silico based virtual screening and mixed mode qm/mm calculation identifies caffeine scaffold for designing potential inhibitors for tyrosyl trna synthetase of mycobacterium tuberculosis. Int J Quantum Chem. 2015;115:187–195.
   Web of Science ®Google Scholar
• Zhu N, Lin Y, Li D, et al. Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase. J Antimicrob Chemother. 2015;70:2287–2294.
   Google Scholar
• Xiao ZP, Wei W, Lin XY, et al. Oxadiazole-inosine derivatives as inhibitors of tyrosyl-tRNA synthetase: synthesis and antibacterial evaluation. CN104231024A; 2014.
   Google Scholar
• Xiao ZP, Wei W, Zhang JW, et al. Oxadiazole - adenosine derivatives as inhibitors of tyrosyl-tRNA synthetase: synthesis and antibacterial evaluation. CN 104262433A; 2014.
   Google Scholar